Scinai Immunotherapeutics Ltd ADR (SCNI) Stock Price, Quote & News

Company Profile

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufac...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 930 2529

Fax: 972 8 930 2531

Website: www.scinai.com

Address:

Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel

Richard_Roma Nov. 14 at 3:06 PM

$SCNI time for company to issue another ridiculously low private placement, then a r/s, to screw baggies further. This will get start when they get possible another NASDAQ delisting notice for being under $1.

0 · Reply

luckysupernova Nov. 13 at 6:53 PM

$SCNI just broke 1. New 52 week low. Management looking for another r/s.

0 · Reply

Biotech_Merchant Nov. 11 at 8:03 PM

$SCNI Interesting LI post from the Scinai team regarding their differentiation in the I&I space, particularly as it pertains to the delivery of their NanoAbs... https://www.linkedin.com/posts/scinai_industry-insight-why-good-data-sometimes-activity-7393746930469593088-p1F4?utm_source=share&utm_medium=member_desktop&rcm=ACoAABZI9dcBz82DdCVH5nC3VgZK_uo5SXnSsC4

1 · Reply

Richard_Roma Nov. 7 at 7:12 PM

$SCNI found in fine dollar stores everywhere

0 · Reply

Khaled43 Nov. 7 at 3:54 PM

$CISS $CNEY $EEIQ $SCNI $SNTG Ciss about to explode

0 · Reply

Khaled43 Nov. 7 at 3:27 PM

$CISS $CNEY $EEIQ $SCNI $SNTG Ciss i think PR next week

0 · Reply

Khaled43 Nov. 7 at 2:42 PM

$CISS $CNEY $EEIQ $SCNI $SNTG I see ciss will explode soooon

0 · Reply

luckysupernova Nov. 6 at 9:29 PM

$SCNI bad tumble. .83 float?

0 · Reply

Richard_Roma Nov. 6 at 4:16 PM

$SCNI their 15 year+ touted "universal flu vaccine" must have been antisemitic too, being effective as salt water. Another Israeli bioturd, you hack.

0 · Reply

Richard_Roma Nov. 5 at 2:39 PM

$SCNI garbage stock. Company has primarily been there to enrich execs. Those who don't learn have to through dilutions and reverse stock splits.

0 · Reply

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Jul 29, 2025, 7:15 AM EDT - 3 months ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jun 12, 2025, 8:00 AM EDT - 5 months ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 5, 2025, 9:00 AM EDT - 5 months ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

May 30, 2025, 7:00 AM EDT - 6 months ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 7, 2025, 4:01 PM EDT - 6 months ago

Scinai Announces Annual Financial Results for 2024

May 1, 2025, 7:00 AM EDT - 7 months ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Mar 27, 2025, 9:25 AM EDT - 8 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 17, 2025, 7:00 AM EDT - 8 months ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 5, 2025, 7:30 AM EST - 9 months ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Jan 6, 2025, 7:31 AM EST - 11 months ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Dec 16, 2024, 9:25 AM EST - 11 months ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 20, 2024, 2:28 PM EDT - 1 year ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 8, 2024, 8:14 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 6, 2024, 9:21 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Scinai leadership to attend BIO-Europe Spring 2024

Feb 29, 2024, 8:45 AM EST - 1 year ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Jan 25, 2024, 10:26 AM EST - 1 year ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 4, 2024, 4:01 PM EST - 2 years ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 6:15 AM EST - 2 years ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Dec 29, 2023, 9:21 AM EST - 2 years ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Dec 27, 2023, 7:15 AM EST - 2 years ago

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Dec 12, 2023, 7:26 AM EST - 2 years ago

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Dec 11, 2023, 8:11 AM EST - 2 years ago

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Nov 29, 2023, 9:25 AM EST - 2 years ago

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Nov 20, 2023, 7:30 AM EST - 2 years ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Richard_Roma Nov. 14 at 3:06 PM

0 · Reply

luckysupernova Nov. 13 at 6:53 PM

$SCNI just broke 1. New 52 week low. Management looking for another r/s.

0 · Reply

Biotech_Merchant Nov. 11 at 8:03 PM

1 · Reply

Richard_Roma Nov. 7 at 7:12 PM

$SCNI found in fine dollar stores everywhere

0 · Reply

Khaled43 Nov. 7 at 3:54 PM

$CISS $CNEY $EEIQ $SCNI $SNTG Ciss about to explode

0 · Reply

Khaled43 Nov. 7 at 3:27 PM

$CISS $CNEY $EEIQ $SCNI $SNTG Ciss i think PR next week

0 · Reply

Khaled43 Nov. 7 at 2:42 PM

$CISS $CNEY $EEIQ $SCNI $SNTG I see ciss will explode soooon

0 · Reply

luckysupernova Nov. 6 at 9:29 PM

$SCNI bad tumble. .83 float?

0 · Reply

Richard_Roma Nov. 6 at 4:16 PM

$SCNI their 15 year+ touted "universal flu vaccine" must have been antisemitic too, being effective as salt water. Another Israeli bioturd, you hack.

0 · Reply

Richard_Roma Nov. 5 at 2:39 PM

$SCNI garbage stock. Company has primarily been there to enrich execs. Those who don't learn have to through dilutions and reverse stock splits.

0 · Reply

Zen_Trades Nov. 4 at 6:34 PM

$SCNI the actual fk is happening here? They have an imperial sht ton of dilution but I didn't expect to see them wholesale dumping into the float until catalyst.

2 · Reply

CrumbEater Nov. 4 at 6:27 PM

$SCNI i'm in for 6k shares.

0 · Reply

Bulltrader988 Nov. 3 at 7:26 PM

$SCNI 👃👀

0 · Reply

Bulltrader988 Nov. 1 at 4:40 PM

$SCNI 👃👀 https://finviz.com/quote.ashx?t=SCNI&ty=c&ta=1&p=d

0 · Reply

Bulltrader988 Oct. 31 at 7:03 PM

$SCNI catalyst next week? 👃👀 "...is heading to #BIOEurope2025 in Vienna!" 👃👀 https://x.com/scinai/status/1973033004705665433?t=XrB2cPIHDYXazXgRAOYUjQ&s=19

0 · Reply

kshonstocks Oct. 28 at 3:29 PM

$SCNI off the bottom chart with upcoming catalyst https://x.com/scinai/status/1973033004705665433

0 · Reply

Zen_Trades Oct. 25 at 8:14 PM

So far $EEIQ is panning out well. Just need to double-check some of the filing exhibits and make sure there's nothing hidden. If not it's lining up for a near-term move that could go triple-digits. Still like $SCNI a lot as well. If I can make the time I'm going to crack the filings on a few that could be settling into bottom plays. Maybe take a look at: $CNEY (~$1.97) 52-week low ~$1.56 $CISS (~$2.14) 52-week low ~$2.00–2.85 $SNTG (~$2.77) 52-week low ~$1.43

0 · Reply

Zen_Trades Oct. 25 at 3:09 AM

Big list to go thru this weekend. This price action could be the beginning of a major move for $EEIQ. .45 goes to 1.00 with a little more attention. $GSIT could have a surprise in store. $SCNX? $SCNI is overdue for a move.

0 · Reply

Cleaner86 Oct. 25 at 2:58 AM

$SCNI lot of bears here. Antisimetic jew haters too. LOOOOSERS lol

0 · Reply

Richard_Roma Oct. 24 at 6:10 PM

$SCNI trash is setting prepped for another 1:10 reverse split, assuming the usual convergence towards <$1.

1 · Reply

pow7904 Oct. 23 at 2:02 PM

$SCNI

0 · Reply

LetsGoBflo Oct. 21 at 12:42 AM

$SCNI crazy bargain price. In for reversal.

0 · Reply

Market Cap	3.49M
Revenue (ttm)	660,000.00
Net Income (ttm)	4.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	727.27%
Debt to Equity Ratio	0.04

Volume	36,000
Avg Vol	87,668
Day's Range	N/A - N/A
Shares Out	3.19M
Stochastic %K	3%
Beta	1.65
Analysts	Strong Buy
Price Target	$8.00